Illumina's divestiture of GRAIL boosts financials, while strong gross margins and DNA sequencing growth drive potential. See ...

Illumina is by far the dominant supplier of sequencing machines to research labs, hospitals and pharmaceutical companies, with a market share of over 75% in the U.S.

Illumina, Inc. (NASDAQ:ILMN) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Illumina, Inc.

Illumina unveiled its MiSeq i100 Series of sequencing systems: two new benchtop instruments, ... The last time Illumina launched a sequencer, the NovaSeqX, was in the fall of 2022.

Illumina's financial flexibility has declined a bit to purchase Grail. Of the $10 billion cumulative purchase price, the company issued about $5 billion of equity, and cash for the remainder ...

Illumina (ILMN) is a technology company that sells sequencing machines and consumables required for genomic testing. This business saw a dramatic rise in demand during the Covid-19 pandemic.

Illumina aims to accelerate its current growth by expanding its core sequencing business, entering multiomics, and expanding its services, data, and software business to provide more complete ...

Medical equipment maker Illumina announced on Wednesday its new series of smaller, low-cost benchtop gene sequencers, to make sequencing accessible to more research and testing labs. Skip to main ...

Illumina (ILMN) stock downgraded to Sell while Charles River (CRL) stock and Hologic (HOLX) stock were upgraded to buy at Citi. Read more here.

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech ...

SAVANA uses a machine learning algorithm to identify cancer-specific structural variations and copy number aberrations in long-read DNA sequencing data. The complex structure of cancer genomes ...